Sort the offer before comparing it
Ask if it is an approved finished medicine.
As of September 26, 2026, FDA-approved products include Ozempic and Wegovy (semaglutide), plus Mounjaro and Zepbound (tirzepatide).
That does not make every preparation carrying either ingredient name approved.
Ask if a pharmacy is making it to order.
Even a well-run pharmacy’s compounded products lack FDA approval as of September 26, 2026.
Question a research-only label.
FDA’s warning as of September 26, 2026, concerns weight-loss products sold for people despite a research label: their quality is unknown, and they could harm health.
Some widely discussed names are different
As of September 26, 2026, no US product for retatrutide, BPC-157 or ipamorelin appears in FDA’s approval records.
As of that date, FDA states that federal compounding law does not allow either retatrutide or cagrilintide.
No approval record means there is no approved US product. That missing record alone does not show whether a product is harmful.
It also does not show whether the law permits a pharmacy to make it to order.
Ask the clinician about the evidence of benefit and harm for the exact product. Ask the pharmacist whether it can legally be made.
A number on a government list is not approval
A National Drug Code, or NDC, identifies an entry in FDA’s drug list. It is a way to list a product, not approve it.
As of September 26, 2026, FDA states that an NDC number or directory entry does not establish FDA approval.
Ask for the approval record for the finished medicine you would receive, rather than a listing for material used to make it.
A record marked BULK INGREDIENT concerns material used to make medicine. That label does not show approval of the finished product.
Ask the clinician or pharmacist to show how the product name in the approval record matches the medicine being offered.
A question to take along
Which exact product are you proposing, and where can I read the record of its approval?